HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients.

Abstract
The presence of comutations (co-mut+) in DNA damage response and repair (DDR) pathways was associated with improved survival for immune checkpoint inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). However, it remains unknown whether co-mut+ status could be a predictive biomarker for immunotherapy. We aimed to explore the predictive role of co-mut+ status in the efficacy of ICIs. A total of 853 NSCLC patients from OAK and POPLAR trials were included in the analyses for the relationship between co-mut status and clinical outcomes with atezolizumab treatment. In co-mut+ NSCLC patients, significantly prolonged progression-free survival (PFS) (p = 0.004) and overall survival (OS) (p < 0.001) were observed in atezolizumab over docetaxel. The interaction between co-mut status and treatment was significant for PFS (p for interaction = 0.010) and OS (p for interaction = 0.017). In patients with negative or low programmed death receptor-ligand 1 expression, co-mut+ status still predicted improved clinical outcomes from atezolizumab therapy. These findings suggested that co-mut status may be a promising predictor of ICI therapy in NSCLC.
AuthorsAnning Xiong, Wei Nie, Yan Zhou, Changhui Li, Kai Gu, Ding Zhang, Shiqing Chen, Fengcai Wen, Hua Zhong, Baohui Han, Xueyan Zhang
JournalFrontiers in immunology (Front Immunol) Vol. 12 Pg. 708558 ( 2021) ISSN: 1664-3224 [Electronic] Switzerland
PMID34630387 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2021 Xiong, Nie, Zhou, Li, Gu, Zhang, Chen, Wen, Zhong, Han and Zhang.
Chemical References
  • Antibodies, Monoclonal, Humanized
  • atezolizumab
Topics
  • Aged
  • Antibodies, Monoclonal, Humanized (therapeutic use)
  • Carcinoma, Non-Small-Cell Lung (drug therapy, genetics)
  • DNA Damage (genetics)
  • DNA Repair (genetics)
  • Female
  • Humans
  • Lung Neoplasms (drug therapy, genetics)
  • Male
  • Middle Aged
  • Mutation
  • Progression-Free Survival
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: